Overview
Abbott Laboratories, based in the United States, is a global healthcare company primarily involved in the development, manufacture, and sale of a broad range of healthcare products. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Key projects of Abbott Laboratories include the development of innovative diagnostic devices, such as rapid testing tools that were pivotal during the COVID-19 pandemic, as well as its continuous work in the cardiology sector, particularly in the manufacturing of life-enhancing vascular devices. The company also focuses on the expansion of its nutritional products line, ensuring growth in both pediatric and adult segments. This strategic diversity across various healthcare fronts solidifies Abbott Laboratories as a leader in the medical field, aiming to improve patient outcomes and access to care worldwide.
AI+ Ask Fintel’s AI assistant about Abbott Laboratories.
Thinking about good questions…
Basic Stats
The Factor Analysis chart (below right) shows a view of Abbott Laboratories from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 1,751.00 MM |
| Earnings Date | |
| EPS (TTM) | 7.98 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-07-15 |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.19 |
| ROE | 0.36 |
| ROIC | 0.22 |
| CROIC | -0.00 |
| OCROIC | 0.14 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 33.53 /100 |
| Profitability | 72.35 /100 |
| Quality Score | 63.65 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | 74.85 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 6.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Abbott Laboratories is CLP123,676.24. The forecasts range from a low of CLP104,210.36 to a high of CLP142,762.50. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Abbott Laboratories. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-07-02 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-06-04 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-05-30 | Goldman Sachs | Buy | Initiate | |
| 2024-05-22 | Citigroup | Buy | Buy | Maintains |
| 2024-04-22 | Barclays | Overweight | Overweight | Maintains |
| 2024-04-18 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-04-04 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-04-03 | Citigroup | Buy | Buy | Maintains |
| 2024-02-14 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-01-26 | Barclays | Overweight | Overweight | Maintains |
| 2024-01-25 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-01-25 | Citigroup | Buy | Buy | Maintains |
| 2024-01-25 | Raymond James | Outperform | Outperform | Maintains |
| 2024-01-11 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-01-03 | Raymond James | Outperform | Outperform | Maintains |
| 2023-12-13 | Wells Fargo | Overweight | Overweight | Maintains |
| 2023-10-19 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-10-19 | Raymond James | Outperform | Outperform | Maintains |
| 2023-10-19 | Wells Fargo | Overweight | Overweight | Maintains |
| 2023-07-24 | Barclays | Overweight | Overweight | Maintains |
| 2023-07-21 | Morgan Stanley | Equal-Weight | Equal-Weight | Reiterate |
| 2023-07-21 | Wolfe Research | Underperform | Peer Perform | Upgrade |
| 2023-04-20 | UBS | Buy | Maintains | |
| 2023-04-20 | Raymond James | Outperform | Maintains | |
| 2023-04-20 | Barclays | Overweight | Maintains | |
| 2023-04-20 | Citigroup | Buy | Maintains | |
| 2023-04-17 | BTIG | Buy | Maintains | |
| 2023-04-17 | Raymond James | Outperform | Maintains | |
| 2023-04-10 | Wells Fargo | Overweight | Maintains | |
| 2023-04-05 | Wells Fargo | Overweight | Maintains | |
| 2023-01-27 | Barclays | Overweight | Maintains | |
| 2023-01-26 | Stifel | Buy | Maintains | |
| 2023-01-26 | Raymond James | Outperform | Maintains | |
| 2023-01-26 | Bernstein | Outperform | Maintains | |
| 2023-01-24 | Mizuho | Neutral | Maintains | |
| 2023-01-06 | Morgan Stanley | Overweight | Maintains | |
| 2022-12-12 | Citigroup | Buy | Maintains | |
| 2022-10-26 | Mizuho | Neutral | Initiate | |
| 2022-10-21 | Barclays | Overweight | Maintains | |
| 2022-10-21 | Raymond James | Outperform | Maintains | |
| 2022-10-20 | RBC Capital | Outperform | Maintains | |
| 2022-10-20 | Morgan Stanley | Overweight | Maintains | |
| 2022-10-18 | Barclays | Overweight | Initiate | |
| 2022-10-17 | BTIG | Buy | Maintains | |
| 2022-10-12 | Jefferies | Hold | Initiate | |
| 2022-10-11 | Morgan Stanley | Overweight | Maintains | |
| 2022-10-10 | Wells Fargo | Overweight | Maintains | |
| 2022-07-27 | UBS | Buy | Maintains | |
| 2022-07-21 | RBC Capital | Outperform | Maintains | |
| 2022-07-21 | Morgan Stanley | Overweight | Maintains | |
| 2022-07-21 | Citigroup | Buy | Maintains | |
| 2022-07-18 | Stifel | Buy | Maintains | |
| 2022-07-18 | BTIG | Buy | Maintains | |
| 2022-07-15 | Morgan Stanley | Overweight | Maintains | |
| 2022-07-15 | Raymond James | Outperform | Maintains | |
| 2022-07-06 | Wolfe Research | Underperform | Initiate | |
| 2022-06-24 | BTIG | Buy | Maintains | |
| 2022-06-07 | Morgan Stanley | Overweight | Maintains | |
| 2022-05-17 | Citigroup | Buy | Maintains | |
| 2022-04-21 | Raymond James | Outperform | Maintains | |
| 2022-04-21 | RBC Capital | Outperform | Maintains | |
| 2022-04-08 | Wells Fargo | Overweight | Maintains | |
| 2022-01-27 | Morgan Stanley | Overweight | Maintains | |
| 2022-01-27 | Raymond James | Outperform | Maintains | |
| 2022-01-07 | Morgan Stanley | Overweight | Maintains | |
| 2021-12-22 | Raymond James | Outperform | Maintains | |
| 2021-12-10 | RBC Capital | Outperform | Initiate | |
| 2021-10-27 | Atlantic Equities | Neutral | Overweight | Upgrade |
| 2021-10-21 | Morgan Stanley | Overweight | Maintains | |
| 2021-10-21 | Raymond James | Outperform | Maintains | |
| 2021-10-21 | SVB Leerink | Market Perform | Maintains | |
| 2021-10-14 | Redburn Partners | Neutral | Initiate | |
| 2021-08-31 | BTIG | Buy | Maintains | |
| 2021-07-23 | Credit Suisse | Outperform | Maintains | |
| 2021-07-23 | Morgan Stanley | Overweight | Maintains | |
| 2021-07-23 | Raymond James | Outperform | Maintains | |
| 2021-07-20 | SVB Leerink | Market Perform | Maintains | |
| 2021-07-12 | Wells Fargo | Overweight | Maintains | |
| 2021-06-02 | Morgan Stanley | Overweight | Maintains | |
| 2021-06-02 | BTIG | Buy | Maintains | |
| 2021-06-02 | Credit Suisse | Outperform | Maintains | |
| 2021-06-02 | Citigroup | Buy | Maintains | |
| 2021-06-02 | Raymond James | Outperform | Maintains | |
| 2021-06-02 | Wells Fargo | Overweight | Maintains | |
| 2021-06-02 | Barclays | Overweight | Maintains | |
| 2021-05-25 | Barclays | Overweight | Initiate | |
| 2021-04-21 | Morgan Stanley | Overweight | Maintains | |
| 2021-04-15 | Atlantic Equities | Neutral | Initiate | |
| 2021-03-11 | Raymond James | Outperform | Maintains | |
| 2021-01-28 | Credit Suisse | Outperform | Maintains | |
| 2021-01-28 | Cowen & Co. | Outperform | Maintains | |
| 2021-01-28 | Morgan Stanley | Overweight | Maintains | |
| 2021-01-28 | Raymond James | Outperform | Maintains | |
| 2021-01-28 | BTIG | Neutral | Buy | Upgrade |
| 2021-01-28 | SVB Leerink | Market Perform | Maintains | |
| 2020-12-15 | Morgan Stanley | Overweight | Maintains | |
| 2020-11-19 | Morgan Stanley | Overweight | Maintains | |
| 2020-10-22 | Jefferies | Buy | Maintains | |
| 2020-10-22 | Credit Suisse | Outperform | Maintains | |
| 2020-10-22 | Morgan Stanley | Overweight | Maintains | |
| 2020-10-22 | Raymond James | Outperform | Maintains | |
| 2020-10-22 | SVB Leerink | Market Perform | Maintains | |
| 2020-09-11 | Wolfe Research | Outperform | Initiate | |
| 2020-08-31 | Credit Suisse | Outperform | Maintains | |
| 2020-08-27 | Morgan Stanley | Overweight | Maintains | |
| 2020-07-20 | B of A Securities | Buy | Maintains | |
| 2020-07-17 | Credit Suisse | Outperform | Maintains | |
| 2020-07-17 | SVB Leerink | Market Perform | Maintains | |
| 2020-07-17 | Morgan Stanley | Overweight | Maintains | |
| 2020-07-17 | Citigroup | Buy | Maintains | |
| 2020-06-25 | Morgan Stanley | Overweight | Maintains | |
| 2020-04-17 | JP Morgan | Overweight | Maintains | |
| 2020-04-17 | Citigroup | Buy | Maintains | |
| 2020-04-17 | UBS | Buy | Maintains | |
| 2020-04-17 | Wells Fargo | Overweight | Maintains | |
| 2020-04-17 | Credit Suisse | Outperform | Maintains | |
| 2020-04-17 | Raymond James | Outperform | Maintains | |
| 2020-04-16 | CFRA | Buy | Maintains | |
| 2020-04-09 | Wells Fargo | Overweight | Maintains | |
| 2020-04-08 | SVB Leerink | Market Perform | Maintains | |
| 2020-04-03 | JP Morgan | Overweight | Maintains | |
| 2020-03-27 | Citigroup | Buy | Maintains | |
| 2020-03-27 | Morgan Stanley | Overweight | Maintains | |
| 2020-03-06 | Credit Suisse | Outperform | Maintains | |
| 2020-03-05 | Citigroup | Buy | Initiate | |
| 2020-02-13 | Goldman Sachs | Neutral | Initiate | |
| 2020-01-23 | UBS | Buy | Maintains | |
| 2020-01-23 | Wells Fargo | Overweight | Maintains | |
| 2020-01-23 | Raymond James | Outperform | Maintains | |
| 2020-01-23 | Stifel Nicolaus | Buy | Maintains | |
| 2020-01-23 | Stifel | Buy | Maintains | |
| 2020-01-02 | Guggenheim Securities | Buy | Neutral | Downgrade |
| 2019-12-17 | Morgan Stanley | Overweight | Maintains | |
| 2019-10-17 | Credit Suisse | Outperform | Maintains | |
| 2019-10-14 | Raymond James | Outperform | Maintains | |
| 2019-07-18 | BMO Capital | Outperform | Maintains | |
| 2019-07-18 | Raymond James | Outperform | Maintains | |
| 2019-07-16 | Morgan Stanley | Overweight | Maintains | |
| 2019-06-13 | Wells Fargo | Outperform | Maintains | |
| 2019-01-02 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2019-01-02 | Citigroup | Neutral | Sell | Downgrade |
| 2018-12-18 | Credit Suisse | Outperform | Initiate | |
| 2018-12-04 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-11-30 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2018-11-28 | UBS | Buy | Initiate | |
| 2018-10-18 | Raymond James | Outperform | Outperform | Maintains |
| 2018-10-16 | Barclays | Overweight | Initiate | |
| 2018-10-11 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-10-08 | JP Morgan | Overweight | Overweight | Maintains |
| 2018-09-24 | Wells Fargo | Outperform | Outperform | Maintains |
| 2018-09-24 | Raymond James | Outperform | Outperform | Maintains |
| 2018-07-19 | Stifel Nicolaus | Buy | Buy | Maintains |
| 2018-06-27 | Bernstein | Outperform | Initiate | |
| 2018-04-24 | Citigroup | Neutral | Neutral | Maintains |
| 2018-01-30 | Citigroup | Neutral | Neutral | Maintains |
| 2018-01-25 | Barclays | Overweight | Overweight | Maintains |
| 2018-01-25 | JP Morgan | Overweight | Overweight | Maintains |
| 2018-01-25 | William Blair | Market Perform | Outperform | Upgrade |
| 2018-01-25 | BMO Capital | Outperform | Outperform | Maintains |
| 2018-01-25 | Stifel Nicolaus | Buy | Buy | Maintains |
| 2018-01-25 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-01-25 | Wells Fargo | Outperform | Maintains | |
| 2018-01-22 | BTIG Research | Buy | Neutral | Downgrade |
| 2018-01-03 | Evercore ISI Group | Outperform | Initiate | |
| 2018-01-02 | JP Morgan | Neutral | Overweight | Upgrade |
| 2018-01-02 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2017-12-12 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2017-10-19 | Barclays | Overweight | Maintains | |
| 2017-10-19 | Morgan Stanley | Equal-Weight | Maintains | |
| 2017-10-19 | Citigroup | Neutral | Maintains | |
| 2017-10-19 | BMO Capital | Market Perform | Maintains | |
| 2017-09-28 | Barclays | Overweight | Maintains | |
| 2017-08-17 | Citigroup | Neutral | Initiate | |
| 2017-07-21 | Deutsche Bank | Buy | Maintains | |
| 2017-07-21 | Argus | Buy | Maintains | |
| 2017-07-10 | Morgan Stanley | Equal-Weight | Maintains | |
| 2017-06-29 | Guggenheim | Buy | Initiate | |
| 2017-05-16 | Goldman Sachs | Neutral | Initiate | |
| 2017-03-14 | BMO Capital | Outperform | Market Perform | Downgrade |
| 2016-09-13 | Jefferies | Buy | Maintains | |
| 2016-08-04 | Jefferies | Buy | Maintains | |
| 2016-07-14 | Jefferies | Buy | Maintains | |
| 2016-06-21 | Edward Jones | Hold | Buy | Upgrade |
| 2016-06-14 | Jefferies | Buy | Maintains | |
| 2016-04-28 | PiperJaffray | Overweight | Neutral | Downgrade |
| 2016-03-15 | Jefferies | Buy | Maintains | |
| 2016-02-05 | Argus | Hold | Buy | Upgrade |
| 2016-01-29 | William Blair | Outperform | Market Perform | Downgrade |
| 2016-01-27 | Jefferies | Buy | Maintains | |
| 2016-01-25 | Leerink Swann | Market Perform | Maintains | |
| 2016-01-14 | Jefferies | Buy | Maintains | |
| 2016-01-04 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2015-12-07 | Jefferies | Hold | Buy | Upgrade |
| 2015-11-13 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2015-10-07 | Barclays | Equal-Weight | Overweight | Upgrade |
| 2015-08-07 | Jefferies | Hold | Maintains | |
| 2015-07-23 | BMO Capital | Outperform | Maintains | |
| 2015-07-23 | Leerink Swann | Market Perform | Maintains | |
| 2015-07-23 | Barclays | Equal-Weight | Maintains | |
| 2015-06-04 | BTIG Research | Buy | Initiate | |
| 2015-05-27 | Evercore ISI Group | Buy | Initiate | |
| 2015-05-26 | Evercore ISI Group | Buy | Initiate | |
| 2015-05-21 | Jefferies | Hold | Maintains | |
| 2015-04-23 | JP Morgan | Neutral | Maintains | |
| 2015-04-23 | Barclays | Equal-Weight | Maintains | |
| 2015-03-10 | Jefferies | Hold | Maintains | |
| 2015-02-20 | Jefferies | Hold | Maintains | |
| 2015-01-30 | Stifel Nicolaus | Buy | Maintains | |
| 2015-01-30 | Barclays | Equal-Weight | Maintains | |
| 2015-01-15 | Jefferies | Hold | Maintains | |
| 2014-12-04 | Jefferies | Buy | Maintains | |
| 2014-10-29 | Deutsche Bank | Hold | Buy | Upgrade |
| 2014-07-17 | Raymond James | Outperform | Maintains | |
| 2014-07-17 | Barclays | Equal-Weight | Maintains | |
| 2014-07-14 | Jefferies | Buy | Maintains | |
| 2014-05-19 | Credit Suisse | Neutral | Outperform | Upgrade |
| 2014-04-21 | Citigroup | Sell | Maintains | |
| 2014-04-17 | Leerink Swann | Market Perform | Maintains | |
| 2014-04-14 | Jefferies | Buy | Maintains | |
| 2014-01-23 | Stifel Nicolaus | Buy | Maintains | |
| 2014-01-17 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2014-01-06 | Morgan Stanley | Equal-weight | Overweight | Upgrade |
| 2013-06-07 | Jefferies | Buy | Maintains | |
| 2013-05-28 | Jefferies | Buy | Maintains | |
| 2013-05-21 | Gabelli & Co. | Buy | Initiate | |
| 2013-05-20 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2013-04-19 | Jefferies | Buy | Maintains | |
| 2013-04-18 | Stifel Nicolaus | Buy | Maintains | |
| 2013-04-12 | Deutsche Bank | Hold | Maintains | |
| 2013-04-12 | Credit Suisse | Neutral | Initiate | |
| 2013-04-10 | Jefferies | Buy | Maintains | |
| 2013-02-15 | Stifel Nicolaus | Buy | Initiate | |
| 2013-02-14 | Stifel Nicolaus | Buy | Initiate | |
| 2013-02-05 | Jefferies | Buy | Maintains | |
| 2013-01-16 | Jefferies | Buy | Maintains | |
| 2013-01-11 | UBS | Buy | Maintains | |
| 2013-01-04 | Deutsche Bank | Buy | Hold | Downgrade |
| 2012-12-20 | William Blair | Outperform | Initiate | |
| 2012-10-18 | Raymond James | Outperform | Market Perform | Downgrade |
| 2012-10-18 | Jefferies | Buy | Maintains | |
| 2012-10-18 | JP Morgan | Neutral | Maintains | |
| 2012-10-15 | Barclays | Equal-Weight | Maintains | |
| 2012-09-19 | Jefferies | Buy | Maintains | |
| 2012-09-14 | UBS | Buy | Maintains | |
| 2012-07-19 | UBS | Buy | Maintains | |
| 2012-07-19 | Citigroup | Sell | Maintains | |
| 2012-07-13 | Jefferies | Buy | Maintains | |
| 2012-06-06 | JP Morgan | Neutral | Maintains | |
| 2012-04-19 | Citigroup | Sell | Maintains | |
| 2012-04-05 | Bank oferica | Neutral | Maintains | |
| 2012-03-29 | JP Morgan | Neutral | Maintains | |
| 2012-03-21 | Credit Suisse | Neutral | Maintains | |
| 2012-03-19 | UBS | Buy | Maintains | |
| 2012-03-08 | Jefferies | Buy | Maintains | |
| 2012-03-01 | UBS | Buy | Maintains | |
| 2024-10-01 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-01-23 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-01-23 | Stifel | Buy | Buy | Maintains |
| 2025-01-23 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-01-23 | UBS | Buy | Buy | Maintains |
| 2024-09-19 | Piper Sandler | Overweight | Initiate | |
| 2024-09-26 | Jefferies | Hold | Hold | Reiterate |
| 2024-10-17 | Mizuho | Neutral | Neutral | Maintains |
| 2024-10-17 | Jefferies | Hold | Hold | Maintains |
| 2024-10-17 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-10-17 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-22 | Citigroup | Buy | Buy | Maintains |
| 2024-10-08 | Oppenheimer | Outperform | Initiate | |
| 2024-07-29 | Barclays | Overweight | Overweight | Maintains |
| 2025-07-16 | Mizuho | Neutral | Neutral | Maintains |
| 2025-07-15 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-10-17 | UBS | Buy | Buy | Maintains |
| 2024-10-17 | Bernstein | Outperform | Outperform | Maintains |
| 2024-10-08 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-10-14 | Raymond James | Outperform | Outperform | Maintains |
| 2024-11-05 | Barclays | Overweight | Overweight | Maintains |
| 2025-04-17 | Barclays | Overweight | Overweight | Maintains |
| 2025-04-17 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-04-17 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-04-17 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-04-17 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2025-04-17 | Raymond James | Outperform | Outperform | Maintains |
| 2025-01-21 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-03-04 | Citigroup | Buy | Buy | Maintains |
| 2025-03-04 | Goldman Sachs | Buy | Buy | Maintains |
| 2025-01-27 | Barclays | Overweight | Overweight | Maintains |
| 2025-03-10 | B of A Securities | Buy | Buy | Maintains |
| 2025-04-17 | Stifel | Buy | Buy | Maintains |
| 2025-04-17 | Jefferies | Hold | Hold | Maintains |
| 2025-07-18 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-07-18 | Raymond James | Outperform | Outperform | Maintains |
| 2025-07-18 | Mizuho | Neutral | Neutral | Maintains |
| 2025-07-18 | Jefferies | Hold | Buy | Upgrade |
| 2025-07-18 | BTIG | Buy | Buy | Maintains |
| 2025-07-15 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-07-08 | Evercore ISI Group | Outperform | Outperform | Maintains |
